LES EMBOLIES ARTERIELLES SYSTEMIQUES RECIDIVANTES CHEZ LES PORTEURS DE PROTHESE VALVULAIRE

Translated title of the contribution: Recurrent systemic arterial embolism in patients with cardiac valve prosthesis

J. Acar, Maurice E Sarano, R. Kassab

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The first 400 cases of 1,436 patients undergoing cardiac valve replacement were analysed to determine the clinical features of recurrent systemic embolism. The average follow-up period was 87 months. Three groups of patients were compared: - A : 289 cases without embolic complications (72.5 p. 100) - B : 78 cases with a single systemic thrombo-embolic event. (TEE) (19,5 p. 100) - C : 33 cases with recurrent TEE (8.25 p. 100). The incidence of recurrence is high (30 p. 100 of cases, 8,1 p. 100 per patient year, compared to 3.8 p. 100 for the first TEE). The site of recurrent embolism was the same in 45 p. 100 of cases. The consequences were serious, 30 to 40 p. 100 of events being associated with death or invalidating sequellae. Four factors predisposed to TEE : mitral valve prosthesis, atrial fibrillation, left atrial dilatation and poor anticoagulant control. Fifty-four months after the first TEE, 60 p. 100 with inadequate anticoagulation had a recurrence compared to 20 p. 100 of patients with satisfactory control. Twenty-six patients (Groups B and C) had operative or autopsy examination of the prosthesis: thrombosis was found in 12 out of 18 cases in Group B, and in 7 out of 8 cases in Group C. Reoperation may be necessary to change the valve (27 out of 1,437 patients). Strict adherence to anticoagulant therapy remains the best prophylaxis against TEE and their recurrence.

Original languageFrench
Pages (from-to)97-101
Number of pages5
JournalAnnales de Medecine Interne
Volume136
Issue number2
StatePublished - 1985
Externally publishedYes

Fingerprint

Heart Valve Prosthesis
Embolism
Recurrence
Anticoagulants
Prostheses and Implants
Heart Valves
Mitral Valve
Reoperation
Atrial Fibrillation
Dilatation
Autopsy
Thrombosis
Incidence

ASJC Scopus subject areas

  • Medicine(all)
  • Internal Medicine

Cite this

LES EMBOLIES ARTERIELLES SYSTEMIQUES RECIDIVANTES CHEZ LES PORTEURS DE PROTHESE VALVULAIRE. / Acar, J.; Sarano, Maurice E; Kassab, R.

In: Annales de Medecine Interne, Vol. 136, No. 2, 1985, p. 97-101.

Research output: Contribution to journalArticle

@article{19c2a3daddf44aae862058aacfecbc59,
title = "LES EMBOLIES ARTERIELLES SYSTEMIQUES RECIDIVANTES CHEZ LES PORTEURS DE PROTHESE VALVULAIRE",
abstract = "The first 400 cases of 1,436 patients undergoing cardiac valve replacement were analysed to determine the clinical features of recurrent systemic embolism. The average follow-up period was 87 months. Three groups of patients were compared: - A : 289 cases without embolic complications (72.5 p. 100) - B : 78 cases with a single systemic thrombo-embolic event. (TEE) (19,5 p. 100) - C : 33 cases with recurrent TEE (8.25 p. 100). The incidence of recurrence is high (30 p. 100 of cases, 8,1 p. 100 per patient year, compared to 3.8 p. 100 for the first TEE). The site of recurrent embolism was the same in 45 p. 100 of cases. The consequences were serious, 30 to 40 p. 100 of events being associated with death or invalidating sequellae. Four factors predisposed to TEE : mitral valve prosthesis, atrial fibrillation, left atrial dilatation and poor anticoagulant control. Fifty-four months after the first TEE, 60 p. 100 with inadequate anticoagulation had a recurrence compared to 20 p. 100 of patients with satisfactory control. Twenty-six patients (Groups B and C) had operative or autopsy examination of the prosthesis: thrombosis was found in 12 out of 18 cases in Group B, and in 7 out of 8 cases in Group C. Reoperation may be necessary to change the valve (27 out of 1,437 patients). Strict adherence to anticoagulant therapy remains the best prophylaxis against TEE and their recurrence.",
author = "J. Acar and Sarano, {Maurice E} and R. Kassab",
year = "1985",
language = "French",
volume = "136",
pages = "97--101",
journal = "Annales de Medecine Interne",
issn = "0003-410X",
publisher = "Masson Publishing",
number = "2",

}

TY - JOUR

T1 - LES EMBOLIES ARTERIELLES SYSTEMIQUES RECIDIVANTES CHEZ LES PORTEURS DE PROTHESE VALVULAIRE

AU - Acar, J.

AU - Sarano, Maurice E

AU - Kassab, R.

PY - 1985

Y1 - 1985

N2 - The first 400 cases of 1,436 patients undergoing cardiac valve replacement were analysed to determine the clinical features of recurrent systemic embolism. The average follow-up period was 87 months. Three groups of patients were compared: - A : 289 cases without embolic complications (72.5 p. 100) - B : 78 cases with a single systemic thrombo-embolic event. (TEE) (19,5 p. 100) - C : 33 cases with recurrent TEE (8.25 p. 100). The incidence of recurrence is high (30 p. 100 of cases, 8,1 p. 100 per patient year, compared to 3.8 p. 100 for the first TEE). The site of recurrent embolism was the same in 45 p. 100 of cases. The consequences were serious, 30 to 40 p. 100 of events being associated with death or invalidating sequellae. Four factors predisposed to TEE : mitral valve prosthesis, atrial fibrillation, left atrial dilatation and poor anticoagulant control. Fifty-four months after the first TEE, 60 p. 100 with inadequate anticoagulation had a recurrence compared to 20 p. 100 of patients with satisfactory control. Twenty-six patients (Groups B and C) had operative or autopsy examination of the prosthesis: thrombosis was found in 12 out of 18 cases in Group B, and in 7 out of 8 cases in Group C. Reoperation may be necessary to change the valve (27 out of 1,437 patients). Strict adherence to anticoagulant therapy remains the best prophylaxis against TEE and their recurrence.

AB - The first 400 cases of 1,436 patients undergoing cardiac valve replacement were analysed to determine the clinical features of recurrent systemic embolism. The average follow-up period was 87 months. Three groups of patients were compared: - A : 289 cases without embolic complications (72.5 p. 100) - B : 78 cases with a single systemic thrombo-embolic event. (TEE) (19,5 p. 100) - C : 33 cases with recurrent TEE (8.25 p. 100). The incidence of recurrence is high (30 p. 100 of cases, 8,1 p. 100 per patient year, compared to 3.8 p. 100 for the first TEE). The site of recurrent embolism was the same in 45 p. 100 of cases. The consequences were serious, 30 to 40 p. 100 of events being associated with death or invalidating sequellae. Four factors predisposed to TEE : mitral valve prosthesis, atrial fibrillation, left atrial dilatation and poor anticoagulant control. Fifty-four months after the first TEE, 60 p. 100 with inadequate anticoagulation had a recurrence compared to 20 p. 100 of patients with satisfactory control. Twenty-six patients (Groups B and C) had operative or autopsy examination of the prosthesis: thrombosis was found in 12 out of 18 cases in Group B, and in 7 out of 8 cases in Group C. Reoperation may be necessary to change the valve (27 out of 1,437 patients). Strict adherence to anticoagulant therapy remains the best prophylaxis against TEE and their recurrence.

UR - http://www.scopus.com/inward/record.url?scp=0022315329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022315329&partnerID=8YFLogxK

M3 - Article

C2 - 4073701

AN - SCOPUS:0022315329

VL - 136

SP - 97

EP - 101

JO - Annales de Medecine Interne

JF - Annales de Medecine Interne

SN - 0003-410X

IS - 2

ER -